Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 21;44(2):277-286.
doi: 10.5937/jomb0-51316.

Changes in tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), matrix metallopeptidase-2/9 (MMP-2/9), and T-lymphocyte subsets in patients undergoing thoracoscopic surgery under refined management for non-small-cell lung cancer

Shuxin Cai  1 , Yannan Zhang  1
Affiliations

Changes in tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), matrix metallopeptidase-2/9 (MMP-2/9), and T-lymphocyte subsets in patients undergoing thoracoscopic surgery under refined management for non-small-cell lung cancer

Shuxin Cai et al. J Med Biochem. .

Abstract
in English, Serbian

Background: Non-small-cell lung cancer (NSCLC) remains one of the most common malignancies worldwide, posing a great potential threat to the health and life safety of patients.

Methods: One hundred and fifty NSCLC patients admitted to our hospital from September 2022 to September 2023 were selected whose inflammatory response and changes in T-lymphocyte subpopulations before and after surgery were detected, and patients' psychological status was investigated. Finally, patients were followed up for 6 months to record the prognostic survival rate.

Results: Postoperative inflammatory factors and CD8 + were lower in the research group than in the control group, while CD3 + , CD4 + and CD4 + /CD8 + were higher than in the control group (P<0.05). Meanwhile, the psychological status of the research group was better. However, the two groups did not differ in prognostic survival (P>0.05).

Conclusions: Perioperative refinement of care can optimize the surgical process in patients with NSCLC, and the cellular immune function was enhanced.

Uvod: Rak pluća ne-malih ćelija (NSCLC) je i dalje jedna od najčešćih malignih bolesti u svetu i predstavlja veliku potencijalnu pretnju po zdravlje i 'životnu bezbednost pacijenata.

Metode: Izabrano je sto pedeset pacijenata sa NSCLC, primljenih u našu bolnicu od septembra 2022. do septembra 2023. godine, kod kojih su detektovani inflamatorni odgovor i promene u subpopulacijama T-limfocita pre i nakon operacije, a istraživano je i psihološko stanje pacijenata. Na kraju su pacijenti praćeni tokom 6 meseci kako bi se zabeležila prognozirana stopa preživljavanja.

Rezultati: Postoperativni inflamatorni faktori i CD8+ su bili niži u grupi koja je ispitivana nego u kontrolnoj grupi, dok su CD3+, CD4+ i CD4+/CD8+ bili viši nego u kontrolnoj grupi (P0.05).

Zaključak: Perioperativno poboljšanje nege može optimizovati hirurški proces kod pacijenata sa NSCLC, a imunska funkcija ćelija je poboljšana.

Keywords: inflammatory response; non-small-cell lung cancer; refined nursing; t lymphocyte subsets; thoracoscopic surgery.

PubMed Disclaimer

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1. The research group had a superior surgical profile.
A: Comparison of surgical time. B: Comparison of intraoperative bleeding. C: Comparison of drainage tube indwelling time.
Figure 2
Figure 2. Postoperative inflammatory response was lower in the research group.
A: Comparison of TNF-α. B: Comparison of IL-6. C: Comparison of MMP-2. D: Comparison of MMP-9. * and # indicate statistically significant differences from the preoperative and control group, respectively (P<0.05).
Figure 3
Figure 3. Better postoperative immune function in the research group.
A: Comparison of CD3+. B: Comparison of CD4+. C: Comparison of CD8+. D: Comparison of CD4+/CD8+. * and # indicate statistically significant differences between the preoperative and control groups (P<0.05).
Figure 4
Figure 4. Better postoperative psychological status in the research group.
A: Comparison of HDMA score. B: Comparison of HAMD score. * and # indicate statistically significant differences between the preoperative and control groups (P<0.05).
Figure 5
Figure 5. Comparison of prognosis.
A: No difference in prognostic 6-month survival between the two groups. B: Comparison of Physical Functioning score. C: Comparison of Role-Physical score. D: Comparison of Bodily Pain score. E: Comparison of General Health score. F: Comparison of Vitality score. G: Comparison of Social Functioning score. H: Comparison of Role-Emotional score. I: Comparison of Mental Health score. # indicate statistically significant differences from the control group (P<0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023;169:115891–115891. doi: 10.1016/j.biopha.2023.115891. - DOI - PubMed
    1. Abu Rous F, Singhi E K, Sridhar A, Faisal M S, Desai A. Lung cancer treatment advances in 2022. Cancer Invest. 2023;41(1):12. doi: 10.1080/07357907.2022.2119479. - DOI - PubMed
    1. Yao J, Novosel M, Bellampalli S, Kapo J, Joseph J, Prsic E. Lung cancer supportive care and symptom management. Hematol Oncol Clin North Am. 2023;37(3):609. doi: 10.1016/j.hoc.2023.02.011. - DOI - PubMed
    1. Jonna S, Subramaniam D S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update. Discov Med. 2019;27(148):167. - PubMed
    1. Du Y, Wen Y, Huang J. Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA. J Med Biochem. 2024;43(3):363. doi: 10.5937/jomb0-37083. - DOI - PMC - PubMed

LinkOut - more resources